TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03486561

Intervention type: DRUG
Group type: OTHER
Intervention: Ranolazine
Description: Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
Study: NCT02003222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Given IV
Study: NCT00800475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemfibrozil Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemfibrozil Tablets
Study: NCT00666536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan and amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan and amlodipine
Study: NCT02327078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose and dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose and dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose and dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose and dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose and dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose and dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose and dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: oral twice daily continuous at the protocol-defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: oral twice daily continuous at the protocol-defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: oral twice daily continuous at the protocol-defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: oral twice daily continuous at the protocol-defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: oral twice daily continuous at the protocol-defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: oral twice daily continuous at the protocol-defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: oral twice daily continuous at the protocol-defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: oral twice daily continuous at the protocol-defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: oral twice daily continuous at the protocol-defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Specified dose on specified days
Study: NCT02003222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT02019329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Oral daily administration from Days 1-12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone
Description: 13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: 13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.
Study: NCT01814813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Description: intradermal infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Description: intradermal infusion
Study: NCT04771039

Intervention type: OTHER
Intervention: reason for consultation
Description: search in medical files for reasons for ophthalmology consultation, functional signs, clinical signs, treatment, characteristics of IBD
Study: NCT05914298

Intervention type: DIAGNOSTIC_TEST
Intervention: blood and buccal swab genetic test
Description: blood samples and buccal swabs will be obtained from patients with HME in order to analyze the genotype (EXT1 or EXT2 mutations) and correlate the genotypic pattern with the phenotypic presentation

Intervention type: DIAGNOSTIC_TEST
Intervention: PUL
Description: measurement of ulnar length with anthropometer and patient's height

Intervention type: DIAGNOSTIC_TEST
Intervention: PUL
Description: measurement of ulnar length with anthropometer and patient's height
Study: NCT02327078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Specified dose on specified days
Study: NCT05914298

Intervention type: DIAGNOSTIC_TEST
Intervention: Range of motion
Description: measurement of range of motion of elbow, forearm and wrist

Intervention type: DIAGNOSTIC_TEST
Intervention: Range of motion
Description: measurement of range of motion of elbow, forearm and wrist
Study: NCT05200091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined explosive strength and specific balance training group
Description: Training will consist to perform one hour of combined ankle explosive strength training and specific balance training using randomized perturbations.~Explosive strength training: Participants will perform only 2 sets of 3 min (12 contractions for each set) for both lower limbs and both ankle plantar- and dorsiflexion movements.~Balance specific training: Participants will be standing, secured by an adjusted harness, which do not support the weight but is strictly there to prevent a fall. They will have online visual feedback of their CoP via an avatar on the screen in front of them. Each training session will consist of 10 sequences of 3 min, including the 5 different conditions:~* Forward tilt of base of support;~* Backward tilt of base of support;~* Translation forward;~* Translation backward;~* Without moving their feet, participants will have to move their avatar to reach different targets placed around them on the screen, at different distance from the center.
Study: NCT01095731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiopronin
Description: Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiopronin
Description: Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
Study: NCT03641274

Intervention type: OTHER
Intervention: Case-management intervention for frequent users of the emergency department
Description: The CM intervention to be implemented is an evidence-based practice. It consists of individualized services based on a detailed baseline evaluation using validated scales to identify all of the social and medical needs of each FUED. The CM team provides counseling and education on health care utilization, substance abuse and the social determinants of health directly to the FUEDs, using skills such as motivational interviewing and cross-cultural competences. Additionally, the CM team provides concrete services including, referral to psychiatric or substance abuse treatment, or medical services (such as a GP or medical specialist), on a case-by-case basis. Another key element of the CM intervention is to connect all health care or social service providers within the hospital or in the community, promoting continuity of care and improving the FUEDs' ability to navigate the complex health care system.
Study: NCT01009632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resonant voice
Description: 4-hr of resonant voice exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice rest
Description: 4-hr of complete refrain from any voice use
Study: NCT01814813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravenous
Study: NCT01009632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spontaneous speech
Study: NCT01382095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE
Description: 10 ug on study days 0, 21 and 42
Study: NCT02868255

Intervention type: PROCEDURE
Intervention: Collection of human samples
Description: Several types of samples will be used to test the effect of the drug candidate

Intervention type: PROCEDURE
Intervention: Collection of human samples
Description: Several types of samples will be used to test the effect of the drug candidate

Intervention type: PROCEDURE
Intervention: Collection of human samples
Description: Several types of samples will be used to test the effect of the drug candidate
Study: NCT02547519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Insulin
Description: Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
Study: NCT01055470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Description: Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
Study: NCT03702855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrabenazine Tablets 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrabenazine Tablets 25 mg
Study: NCT02936336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: circuit exercise, aerobic dance and Tai Chi exercise
Study: NCT03718676

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ferric sulphate
Description: Teeth were pulpotomized with ferric sulphate in this group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ortho-MTA
Description: Teeth were pulpotomized with Ortho-MTA in this group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retro-MTA
Description: Teeth were pulpotomized with Retro-MTA in this group.
Study: NCT05255341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: roll pedicle connective tissue graft with bovine bone
Description: rotated pedicle connective tissue graft together with bovine bone applied for socket preservation after tooth extraction
Study: NCT04192760

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting
Description: Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting
Description: Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions
Study: NCT03127553

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-sodium diet with standard bread
Description: low-sodium diet (2300 mg Na/die) with use of standard bread (750 mg Na/100g) for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-sodium diet with low-sodium bread
Description: low-sodium diet (2300 mg Na/die) with use of low-salt bread (280 mg Na/100g) for 6 months
Study: NCT00129740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 400 mg orally twice daily
Study: NCT01956994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplement
Description: Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate supplement
Description: Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
Study: NCT02480803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous intrajejunal infusion of levodopa-carbidopa
Description: Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Study: NCT00643799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule once daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 500 mg oral capsule twice daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo for 6 months
Study: NCT00578422

Intervention type: OTHER
Intervention: Ivus (Intravascular Ultrasound) of Amputation Specimens
Description: Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques

Intervention type: PROCEDURE
Intervention: IVUS (Intravascular Ultrasound)
Description: Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
Study: NCT04450342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation
Description: The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue. The REGENETEN Bioinductive Implant is a bioabsorbable implant device that provides a layer of collagen over injured tendons. The implant is designed to provide a layer of collagen between a flat tendon and the surrounding tissue. After hydration, the implant is an easy-to-handle, pliable, nonfriable, porous collagen sheet.
Study: NCT01814813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: intravenous
Study: NCT04450342

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arthroscopic rotator cuff repair
Description: The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear without supplement.

Intervention type: DEVICE
Group type: OTHER
Intervention: Arthroscopic rotator cuff repair for revision surgery
Description: The Arthroscopic rotator cuff repair can also occur in recurrent tears. The REGENETEN Bioinductive Implant will be applied during the ARCR procedure.
Study: NCT03706040

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Risankizumab
Description: subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: subcutaneous (SC) injection
Study: NCT02020928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low level laser therapy
Description: Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.
Study: NCT00134017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Days -7 to -4: 4 mg/kg PO daily OR 3.2 mg/kg IV daily OR 160 mg/m\^2 daily (for pediatric recipients)
Study: NCT04182204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle IV on Day 1 of each 21-day cycle for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle IV on Day 1 of each 21-day cycle for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for up to 8 cycles.
Study: NCT00134017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -3, -2, +3, +4: 50 mg/kg IV daily
Study: NCT01600391

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overground visual cue training
Description: Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill visual cue training
Description: Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
Study: NCT00876486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM®
Description: Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genexol®
Description: Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks